The Dismal Disease: Temozolomide and the Interaction of Evidence
“I think the challenge is really that we still, not only in glioblastoma, but in oncology at large, treat the majority of patients with a one-size-fits-all approach.” — Roger Stupp Blockbuster drugs are rare. To be a blockbuster, a drug must shift over $1bn worth in one year. There …